Our Patients

At Proclara, we are working towards a singular goal: improving the lives of patients and families affected by Alzheimer’s and other neurodegenerative diseases. Like you, we understand the urgent need for new treatments for these devastating diseases.
As we work to advance our pipeline of novel therapies and meet the great unmet need for new treatments, we strive to put patients, caregivers, and their families at the center of our efforts. We are inspired by your strength and resilience and committed to delivering innovative therapies with the potential to create a real difference in your lives.

To learn about enrolling in our clinical trial, please click the button below:

Clinical Trials

Proclara is currently conducting a Phase 1b study of its lead product candidate, NPT088, for the treatment of Alzheimer’s disease. NPT088 is a fusion protein combining GAIM with the backbone of a human immunoglobulin, and is delivered by intravenous administration. In animal studies, it acts on both protein aggregates implicated in Alzheimer's disease — amyloid-β (Aβ) and tau — meaning NPT088 may be better suited to treat the complex pathophysiology of the disease than other monotherapies currently in development.


NPT088-CL002 Study

CL002, a Phase 1b clinical trial to evaluate NPT088, is a multicenter, randomized, double-blind, placebo-controlled,
multiple-dose, dose-escalation safety and tolerability study of NPT088 or placebo in patients with probable Alzheimer’s disease with an MMSE score of 18-27. Enrolled patients will receive an intravenous infusion of NPT088 or placebo once a month for six months during this study. Four dose cohorts are planned, with patients in each cohort receiving NPT088 or placebo in a 2 to 1 ratio. The first two cohorts will enroll 9 patients each (6 NPT088: 3 placebo) and the final two cohorts will enroll 24 patients each (16 NPT088: 8 placebo) for a total of 66 patients (44 NPT088: 22 placebo).

The study’s primary objective is to assess the safety and tolerability of multiple doses of NPT088 in patients with mild to moderate Alzheimer’s disease. The study will also evaluate the pharmacokinetics, immunogenicity and exploratory pharmacodynamic characteristics of multiple doses of NPT088, as measured by amyloid-β and tau PET imaging.

To learn about this study, including clinical trial locations:

To learn more about the Alzheimer's Association's Part the Cloud program:


For more information about Alzheimer’s disease, visit http://www.alz.org

For more information about Parkinson’s disease, visit http://www.michaeljfox.org

PETscan image: top - 63 yrs old patient with probable Alzheimer's Disease, bottom - 53 yrs old control subject without dementia.

Piramal Imaging 2017